Drug intelligence / Profile preview

BT002

Development stage: Preclinical
Lead developer: Bone-Tech
Modality: Small Molecules
Administration: Parenteral

Overview

**BT002**, also called **OsteoActivator-M**, is a preclinical, locally administered extended-release combination product being developed for bone repair and osteoarthritis-associated subchondral bone remodeling. It uses injectable biodegradable poly(lactic-co-glycolic acid) microspheres to provide sustained local delivery of testosterone, intended to enhance osteoblast-mediated bone formation, together with alendronate, intended to inhibit osteoclast-mediated bone resorption. The product is intended for osteoarthritis, bone defects and trauma-related injuries, including vertebral compression fractures. ([osteo-pharma.com](https://www.osteo-pharma.com/product-pipeline/))

Brand names: OsteoActivator-M
Other names: OsteoActivator-M

Targets

FDPS (Farnesyl pyrophosphate synthase)AR (Adrenergic receptors)

Beyond the preview

Go deeper on BT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT002.

Explore the full profile